Get a glimpse into our company and investor data—powered by the PitchBook Platform
Series ALATEST DEAL TYPE
$46MLATEST DEAL AMOUNT
Developer of an online platform for providing immunotherapy services. The company is focused on the specific modulation of immune cell subsets based on novel platform technologies to address intractable cancers particularly solid tumors.